Related references
Note: Only part of the references are listed.Prevalence of statin intolerance: a meta-analysis
Ibadete Bytyci et al.
EUROPEAN HEART JOURNAL (2022)
The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury
Abigail R. Bland et al.
PHARMACOLOGICAL RESEARCH (2022)
Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
Massimiliano Ruscica et al.
CARDIOVASCULAR RESEARCH (2022)
Atherosclerosis: Recent developments
Johan L. M. Bjoerkegren et al.
CELL (2022)
High-Intensity Statin Use Among Patients With Atherosclerosis in the US
Adam J. Nelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Pathogenic mitochondrial dysfunction and metabolic abnormalities
Walter H. Moos et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Extensor carpi ulnaris muscle shows unexpected slow-to-fast fiber-type switch in Duchenne muscular dystrophy dogs
Chady H. Hakim et al.
DISEASE MODELS & MECHANISMS (2021)
ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders
Xi Cao et al.
CLINICAL SCIENCE (2021)
Effects of statins on mitochondrial pathways
Hamid Mollazadeh et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)
Cholesterol: the race to the bottom
Eugene Braunwald
EUROPEAN HEART JOURNAL (2021)
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
Peter E. Penson et al.
EUROPEAN HEART JOURNAL (2021)
Axonal GABAA stabilizes excitability in unmyelinated sensory axons secondary to NKCC1 activity
Veronica Bonalume et al.
JOURNAL OF PHYSIOLOGY-LONDON (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease
Fatima Rodriguez et al.
JAMA CARDIOLOGY (2019)
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Connie B. Newman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Statin Toxicity Mechanistic Insights and Clinical Implications
Natalie C. Ward et al.
CIRCULATION RESEARCH (2019)
Statins: Adverse reactions, oxidative stress and metabolic interactions
Aimei Liu et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism
Neeltje A. E. Allard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
AMPK: guardian of metabolism and mitochondrial homeostasis
Sebastien Herzig et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Pharmacological validation of voluntary gait and mechanical sensitivity assays associated with inflammatory and neuropathic pain in mice
Andrew J. Shepherd et al.
NEUROPHARMACOLOGY (2018)
Mitochondrial function as a therapeutic target in heart failure
David A. Brown et al.
NATURE REVIEWS CARDIOLOGY (2017)
Animal models of atherosclerosis
Besa Emini Veseli et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment
William M. Southern et al.
PLOS ONE (2017)
Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013
Toke de Koning Svendsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence
Caterina Tezze et al.
CELL METABOLISM (2017)
Gait analysis methods for rodent models of arthritic disorders: reviews and recommendations
E. H. Lakes et al.
OSTEOARTHRITIS AND CARTILAGE (2016)
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Stephen L. Pinkosky et al.
NATURE COMMUNICATIONS (2016)
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Joseph L. Goldstein et al.
CELL (2015)
The Opa1-Dependent Mitochondrial Cristae Remodeling Pathway Controls Atrophic, Apoptotic, and Ischemic Tissue Damage
Tatiana Varanita et al.
CELL METABOLISM (2015)
Opa1 Overexpression Ameliorates the Phenotype of Two Mitochondrial Disease Mouse Models
Gabriele Civiletto et al.
CELL METABOLISM (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
The role of mitochondria in statin-induced myopathy
Maria Apostolopoulou et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
Statin-Induced Increases in Atrophy Gene Expression Occur Independently of Changes in PGC1α Protein and Mitochondrial Content
Craig A. Goodman et al.
PLOS ONE (2015)
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
Mary A. De Vera et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity
Louise Lantier et al.
FASEB JOURNAL (2014)
Effect of Statins on Skeletal Muscle Function
Beth A. Parker et al.
CIRCULATION (2013)
Simvastatin Impairs Exercise Training Adaptations
Catherine R. Mikus et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Association of statin use with peripheral neuropathy in the US population 40 years of age or older
Edward F. Tierney et al.
JOURNAL OF DIABETES (2013)
Clinical response to statins: Mechanism(s) of variable activity and adverse effects
Cesare R. Sirtori et al.
ANNALS OF MEDICINE (2012)
Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a omitohormesis' mechanism involving reactive oxygen species and PGC-1
Jamal Bouitbir et al.
EUROPEAN HEART JOURNAL (2012)
Gait analysis as a method for assessing neurological outcome in a mouse model of stroke
Susann Hetze et al.
JOURNAL OF NEUROSCIENCE METHODS (2012)
Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
P. Sirvent et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol
Tiffany Mailman et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Microgenomic Analysis in Skeletal Muscle: Expression Signatures of Individual Fast and Slow Myofibers
Francesco Chemello et al.
PLOS ONE (2011)
The effects of statins on skeletal muscle strength and exercise performance
Guru M. Krishnan et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Altered peripheral myelination in mice lacking GABAB receptors
Valerio Magnaghi et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2008)
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study
S. Pierno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems
H Sinzinger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes -: 1999-2000 National Health and Nutrition Examination Survey
EW Gregg et al.
DIABETES CARE (2004)
Disorder resembling Guillain-Barre syndrome on initiation of statin therapy
YA Rajabally et al.
MUSCLE & NERVE (2004)
Statin-associated myopathy with normal creatine kinase levels
PS Phillips et al.
ANNALS OF INTERNAL MEDICINE (2002)
Statins and risk of polyneuropathy -: A case-control study
D Gaist et al.
NEUROLOGY (2002)
Regular review - Peripheral neuropathy
RAC Hughes
BRITISH MEDICAL JOURNAL (2002)
Expressing the magnitude of adverse effects in case-control studies: the number of patients needed to be treated for one additional patient to be harmed
LM Bjerre et al.
BRITISH MEDICAL JOURNAL (2000)
Share Paper
